Key Highlights

  • Palantir Technologies (NASDAQ:PLTR) was down 7.36% to USD 165.22 in pre-market trading on November 3, 2026, after Revenue rose 96% to USD 2.313 billion.
  • Bioventus (NASDAQ:BVS) was down 19.47% to USD 10.59 in pre-market trading on November 3, 2026, despite higher profit and a USD 15.0 million term Loan prepayment.
  • Adeia (NASDAQ:ADEA) was down 22.11% to USD 16.10 in pre-market trading on November 3, 2026, after a lower 2026 revenue range.
  • Emergent BioSolutions (NYSE:EBS) was down 18.63% to USD 5.24 in pre-market trading on November 3, 2026, with revenue down 52%.
  • AI OKTO (NASDAQ:AIOK) was down 17.56% to USD 10.41 in pre-market trading on November 3, 2026, with no new announcement identified.

Palantir Technologies (NASDAQ:PLTR) (down USD 13.13, 7.36%): Pullback After a Blowout Quarter

Palantir Technologies (NASDAQ:PLTR) was down 7.36% to USD 165.22 in pre-market trading on November 3, 2026, against a Monday close of about USD 178.34. Third quarter revenue rose 96% to USD 2.313 billion, US commercial revenue climbed 148% to USD 984 million, and the adjusted Operating Margin was 62%.

The company raised full year 2026 revenue guidance to USD 8.530 billion to USD 8.534 billion. No specific cause for the decline was stated, but total contract value closed was USD 2.918 billion, up only 6% year over year, compared with growth of 49% in the second quarter of 2026.

Bioventus (NASDAQ:BVS) (down USD 2.56, 19.47%): Higher Profit, Modest Sales Growth

Bioventus (NASDAQ:BVS) was down 19.47% to USD 10.59 in pre-market trading on November 3, 2026, after its third quarter report on November 2, 2026. Net sales were USD 142.4 million, up 2.7%, and adjusted EBITDA rose to USD 28.4 million from USD 26.6 million.

The company reaffirmed 2026 adjusted Earnings Per Share guidance of USD 0.75 to USD 0.79. It continues to review strategic alternatives, and no transaction was announced. Restorative Therapies sales were down 3.4%, and U.S. sales grew only 1.0% to USD 124.6 million.

Adeia (NASDAQ:ADEA) (down USD 4.57, 22.11%): Revenue Range Lowered

Adeia (NASDAQ:ADEA) was down 22.11% to USD 16.10 in pre-market trading on November 3, 2026. Third quarter revenue was USD 80.2 million against USD 87.3 million a year earlier, a decline of about 8.1% (calculated), and adjusted EBITDA fell to USD 36.9 million from USD 50.7 million.

The 2026 revenue range was lowered to USD 375.0 million to USD 415.0 million from USD 395.0 million to USD 435.0 million. Management said the timing of a few deals could push some revenue beyond year-end. Term loan principal was USD 386.5 million against USD 127.7 million of cash and marketable securities.

Emergent BioSolutions (NYSE:EBS) (down USD 1.20, 18.63%): Steep Revenue Decline

Emergent BioSolutions (NYSE:EBS) was down 18.63% to USD 5.24 in pre-market trading on November 3, 2026, after results released on November 2, 2026. Revenue was USD 110.0 million, down 52% from USD 231.1 million, and the net loss was USD 32.7 million.

Naloxone sales fell to USD 43.5 million and smallpox countermeasure sales fell to USD 26.7 million, which the company attributed mainly to U.S. government timing. Anthrax countermeasure sales rose to USD 25.1 million. Revenue guidance was lowered to USD 600 million to USD 645 million, and the chief financial officer will retire effective December 31, 2026. The release did not disclose cash or total Debt balances.

AI OKTO (NASDAQ:AIOK) (down USD 2.22, 17.56%): A Reversal After the Dividend Spike

AI OKTO (NASDAQ:AIOK) was down 17.56% to USD 10.41 in pre-market trading on November 3, 2026, from a prior close of roughly USD 12.63 (calculated). This is not an earnings story. No company announcement dated November 2 or November 3, 2026 was identified, and market data indicated the stock had already dropped sharply on Monday.

The company declared a Special Dividend of USD 3.50 per share on October 23, 2026, payable in cash or common shares, with an expected ex-dividend date of November 26, 2026. It also announced the sale of the LPG carrier Dream Arrax. The share count is roughly 4.32 million, and a USD 500 million shelf registration was filed in October 2026, so swings can be outsized.

Where Things Stand

The five stocks fell for different reasons. Palantir (NASDAQ:PLTR) slipped despite record growth, with slowing contract value growth the softer data point. Bioventus (NASDAQ:BVS) fell despite higher profit, Adeia (NASDAQ:ADEA) and Emergent BioSolutions (NYSE:EBS) lowered guidance, and AI OKTO (NASDAQ:AIOK) fell with no fresh news. What to watch is whether regular trading on November 3, 2026 confirms the pre-market declines, whether Bioventus provides strategic review updates, and how Adeia and Emergent perform against their revised ranges.